ClinicalTrials.gg
RecruitingNCT06429176Updated Nov 10, 2026

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

A Phase 2 interventional study of SPL84 and Placebo in Cystic Fibrosis, sponsored by SpliSense Ltd.. Recruiting at 27 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by SpliSense Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.
Updated Nov 10, 2026First sites in 8 new countriesSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
170th of 517
64 · median 36
Started
2024
with 29 others
Phase 2
103 of 717
10 open now
Primary completion
2027-10
later than 67 of 108 live
Registered
668th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 170th largest by planned enrollment of the 517 interventional ones that give a count, is one of 30 that started in 2024, is one of 103 in phase 2, reaches primary completion later than 67 of the 108 other live ones, and was the 668th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation (3849 +10kb C-->T).

The purpose of this research study is to test the safety and effectiveness of multiple doses of the study drug, SPL84.

Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug SPL84 is safe and if it works to treat CF. In cohorts 1-3, SPL84 will be tested as a monotherapy, and in Cohort 4, SPL84 will be tested in participants who are already stable on CFTR modulator therapy.

Participants will take drug SPL84 or a placebo by inhalation every week for 9 weeks (cohorts 1-3) or 12 weeks (cohort 4) and visit the clinic approximately weekly for checkups and tests.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Cohort 1-3:

Inclusion Criteria:

  • Diagnosis of CF and two CF causing mutations; 3849+10 Kb C->T mutation on one allele in the CF transmembrane conductance regulator (CFTR) gene (homozygote or compound heterozygote). Source documentation from a certified genetic laboratory is required.
  • (BMI) of ≥ 17 kg/m2.
  • 40-90% predicted at screening.
  • Non-smokers or vapers for at least 180 days (6 months) prior to screening, per participant report.

Exclusion Criteria:

  • Use of Kalydeco, Orkambi, Symdeko/Symkevi or Trikafta/Kaftrio within 30 days of first dose with study intervention.
  • Use of any drug (other than SPL84) or device within 30 days of first dose with study intervention.
  • Use of systemic over 3 consecutive months in the last 6 months prior to screening, or use of systemic steroids in the last month prior to screening. Use of inhaled steroids above 1 mg.
  • Use of CF medications, e.g. inhaled antibiotics, dornase alfa (Pulmozyme), hypertonic saline and physiotherapy should be on stable regimen for the period 28 days prior to screening; those participants taking inhaled antibiotics for prophylaxis must be on a stable regimen of these drugs for at least 90 days prior to first dose with study intervention.
  • Any acute infection including acute upper respiratory or lower respiratory infections, pulmonary exacerbation, changes in therapy for pulmonary disease, or any non CF-related illness which results in the initiation of any new therapy within 14 days prior to first dose with study intervention.
  • Hemoptysis of greater than 30 mL within 90 days prior to Day 1, or hospitalization for hemoptysis within 6 months of first dose with study intervention.
  • Liver disease characterized by cirrhosis and/or documented portal hypertension.
  • History of any organ transplantation.
  • Documented coronavirus disease (COVID-19) infection within 4 weeks prior to dosing.

Cohort 4:

Inclusion Criteria:

  • Diagnosis of CF and two CF causing mutations; 3849+10 Kb C->T mutation on one allele in the CF transmembrane conductance regulator (CFTR) gene (homozygote or compound heterozygote). Source documentation from a certified genetic laboratory is required.
  • Body mass index (BMI) of ≥ 17 kg/m2.
  • FEV1 40-80% predicted at screening.
  • Non-smokers or vapers for at least 180 days (6 months) prior to screening, per participant report.
  • Stable adherence to standard use of Trikafta/Kaftio or Alyftrek for at least 3 months, or Alyftrek for 1 month after switching from Trikafta/Kaftio, according to prescribing information.

Exclusion Criteria:

  • Previous participation in active arm of SPL84-002 study (Cohort 1-3)
  • Use of any investigational drug (other than SPL84) or device within 30 days of first dose with study intervention.
  • Use of systemic steroids over 3 consecutive months in the last 6 months prior to screening, or use of systemic steroids in the last month prior to screening. Use of inhaled steroids above 1 mg.
  • Use of CF medications, e.g. inhaled antibiotics, dornase alfa (Pulmozyme), hypertonic saline and physiotherapy should be on stable regimen for the period 28 days prior to screening; those participants taking inhaled antibiotics for prophylaxis must be on a stable regimen of these drugs for at least 90 days prior to first dose with study intervention.
  • Any acute infection including acute upper respiratory or lower respiratory infections, pulmonary exacerbation, changes in therapy for pulmonary disease, or any non CF-related illness which results in the initiation of any new therapy within 14 days prior to first dose with study intervention.
  • Hemoptysis of greater than 30 mL within 90 days prior to Day 1, or hospitalization for hemoptysis within 6 months of first dose with study intervention.
  • Liver disease characterized by clinically significant cirrhosis and/or documented portal hypertension.
  • History of any organ transplantation.
  • Documented coronavirus disease (COVID-19) infection within 4 weeks prior to dosing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    SPL84

    Drug: SPL84

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugSPL84

    SPL84 solution for nebulization

  • OtherPlacebo

    Placebo solution for nebulization

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)

    Incidence, nature, and severity of AEs and SAEs

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  2. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rate

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  3. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rate

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  4. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressure

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  5. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetry

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  6. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperature

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  7. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test results

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  8. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test results

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  9. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test results

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  10. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parameters

    using an ECG machine that automatically calculates heart rate and measure PR, QRS, QT, and QTc intervals

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  11. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findings

    Complete physical examinations include general appearance, head, ears, eyes, nose, throat, thyroid, chest (heart, lungs), abdomen, skin, neurological, extremities, back, neck, musculoskeletal, and lymph nodes.

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  12. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal pulmonary function tests results

    Pulmonary function tests will be performed according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) and forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and forced mid-expiratory flow (FEF25-75) will be measured

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  13. Safety and Tolerability of SPL84 as assessed by number of participants with abnormal immunogenicity results

    assessment of anti-SPL84 antibodies will be performed both in serum and sputum

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

Secondary outcomes

  1. Characterization of pharmacokinetics (PK) of SPL84: maximum serum concentration (Cmax)

    Time frame: Cohort 1-3: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87; Cohort 4: Predose and 1, 3, and 6 hours post dose on Days 1 and 78

  2. Characterization of PK of SPL84: Time to Cmax (Tmax)

    Time frame: Cohort 1-3: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87; Cohort 4: Predose and 1, 3, and 6 hours post dose on Days 1 and 78

  3. Characterization of PK of SPL84: terminal elimination half-life (t1/2)

    Time frame: Cohort 1-3: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87; Cohort 4: Predose and 1, 3, and 6 hours post dose on Days 1 and 78

  4. Characterization of PK of SPL84: Area under the curve to the final sample (AUC0-t)

    Time frame: Cohort 1-3: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87; Cohort 4: Predose and 1, 3, and 6 hours post dose on Days 1 and 78

  5. Characterization of PK of SPL84: Area under the curve to infinity (AUC0-∞)

    Time frame: Cohort 1-3: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87; Cohort 4: Predose and 1, 3, and 6 hours post dose on Days 1 and 78

  6. Characterization of PK of SPL84: Apparent clearance (CL/F)

    Time frame: Cohort 1-3: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87; Cohort 4: Predose and 1, 3, and 6 hours post dose on Days 1 and 78

  7. Characterization of excretion of SPL84: concentration of SPL84 in urine

    Time frame: Day 1 through Day 87 (Cohort 1-3) or Day 85 (Cohort 4)

  8. Efficacy of SPL84 as assessed by change from baseline in percent predicted FEV1

    Pulmonary function tests will be performed according to the ATS/ERS

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  9. Efficacy of SPL84 as assessed by change from baseline in percent predicted FEF25-75

    Time frame: Day 1 to Day 87 (Cohort 1-3) or Day 108 (Cohort 4)

  10. Efficacy of SPL84 as assessed by change from baseline in Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score

    The score for is standardized on a 0- to 100-point scale on which higher scores represent a higher quality of life

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  11. Efficacy of SPL84 as assessed by change from baseline in body weight

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  12. Preliminary efficacy of SPL84 as assessed by change from baseline of antibiotic treatment (Cohort 1-3 only)

    Time frame: Day 1 through Day 87

  13. Cohort 1-3: Safety and Tolerability of SPL84 as assessed by number of participants with abnormal sputum microbiology results Cohort 4: Exploratory efficacy of SPL84 as assessed by number of participants with change in abnormal sputum microbiology result

    Sputum microbiology will be performed with a microbiology based assay; organism growth will be identified.

    Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)

  14. Exploratory efficacy of SPL84 as assessed by number of participants with change in Lung Clearance Index at 2.5% of starting concentration (LCI2.5)

    Measured using multiple breath washout (at select study sites only)

    Time frame: Day 1 to Day 85

07

Study locations

14 of 27 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Oct 2027, 39 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 39 months is above that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 24, 2024
StartActual
Jun 24, 2024
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
24 sites added — first sites in Czechia, France, Germany, Israel, Italy and 3 more
All 8 countries

Czechia, France, Germany, Israel, Italy, Lithuania, Poland, Spain

. Boston Children'S Hospital is now Recruiting
Show 24 added (13 United States, 2 Germany, 2 Israel, 2 Poland, 1 Czechia, 1 France, 1 Italy, 1 Lithuania, 1 Spain)
  • Memorial Care Long Beach Medical Center · Long Beach, United States
  • University of California, San Francisco · San Francisco, United States
  • University of California Los Angeles · Santa Monica, United States
  • Joe DiMaggio Children's Hospital · Hollywood, United States
  • Northwestern University · Chicago, United States
  • University of Minnesota · Minneapolis, United States
  • Lenox Hill Cystic Fibrosis Center · New York, United States
  • Columbia University Cystic Fibrosis Program · New York, United States
  • University of North Carolina at Chapel Hill · Chapel Hill, United States
  • University of Pennsylvania · Philadelphia, United States
  • University of Utah · Salt Lake City, United States
  • Inova Fairfax Hospital · Falls Church, United States
  • University of Washington Medical Center · Seattle, United States
  • Motol University Hospital · Prague, Czechia
  • Centre Hospitalier Régional Universitaire (CHRU) de Montpellier · Montpellier, France
  • Charité - Universitätsmedizin Berlin · Berlin, Germany
  • Klinikum Westbrandenburg CF Zentrum Potsdam · Potsdam, Germany
  • Hadassah Mt. Scopus Hospital · Jerusalem, Israel
  • Rabin Medical Center (Beilinson Hospital) · Petah Tikva, Israel
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico · Milan, Italy
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics · Kaunas, Lithuania
  • Kliniki Pulmonologii, Alergologii i Onkologii Pulmonologicznej Uniwersytetu Medycznego im.Karola Marcinkowskiego w Poznaniu · Poznan, Poland
  • Instytut Gruźlicy i Chorób Płuc Oddział Terenowy im. Jana i Ireny Rudników · Rabka-Zdrój, Poland
  • Vall d'Hebron Barcelona Hospital Campus · Barcelona, Spain
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    24 sites added — first sites in Czechia, France, Germany, Israel, Italy and 3 more
    All 8 countries

    Czechia, France, Germany, Israel, Italy, Lithuania, Poland, Spain

    . Boston Children'S Hospital is now Recruiting
    Show 24 added (13 United States, 2 Germany, 2 Israel, 2 Poland, 1 Czechia, 1 France, 1 Italy, 1 Lithuania, 1 Spain)
    • Memorial Care Long Beach Medical Center · Long Beach, United States
    • University of California, San Francisco · San Francisco, United States
    • University of California Los Angeles · Santa Monica, United States
    • Joe DiMaggio Children's Hospital · Hollywood, United States
    • Northwestern University · Chicago, United States
    • University of Minnesota · Minneapolis, United States
    • Lenox Hill Cystic Fibrosis Center · New York, United States
    • Columbia University Cystic Fibrosis Program · New York, United States
    • University of North Carolina at Chapel Hill · Chapel Hill, United States
    • University of Pennsylvania · Philadelphia, United States
    • University of Utah · Salt Lake City, United States
    • Inova Fairfax Hospital · Falls Church, United States
    • University of Washington Medical Center · Seattle, United States
    • Motol University Hospital · Prague, Czechia
    • Centre Hospitalier Régional Universitaire (CHRU) de Montpellier · Montpellier, France
    • Charité - Universitätsmedizin Berlin · Berlin, Germany
    • Klinikum Westbrandenburg CF Zentrum Potsdam · Potsdam, Germany
    • Hadassah Mt. Scopus Hospital · Jerusalem, Israel
    • Rabin Medical Center (Beilinson Hospital) · Petah Tikva, Israel
    • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico · Milan, Italy
    • Hospital of Lithuanian University of Health Sciences Kaunas Clinics · Kaunas, Lithuania
    • Kliniki Pulmonologii, Alergologii i Onkologii Pulmonologicznej Uniwersytetu Medycznego im.Karola Marcinkowskiego w Poznaniu · Poznan, Poland
    • Instytut Gruźlicy i Chorób Płuc Oddział Terenowy im. Jana i Ireny Rudników · Rabka-Zdrój, Poland
    • Vall d'Hebron Barcelona Hospital Campus · Barcelona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06429176
Lead sponsor
SpliSense Ltd.
Responsible party
Sponsor
First posted
May 24, 2024
Start date
Jun 24, 2024
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 10, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion